Mereo BioPharma Reports $6.7 Million Net Loss in Q1 2026, Improved from Previous Year

Mereo BioPharma Group plc reported a net loss of $6.7 million for the first quarter of 2026, a significant improvement compared to a net loss of $12.9 million in the same period of the previous year. The company’s operating expenses totaled $8.8 million, down from $11.2 million year-over-year, primarily due to a reduction in general and administrative expenses, which decreased by $3.3 million to $4.0 million. Research and development expenses increased by $0.8 million to $4.7 million, driven mainly by costs associated with the development of setrusumab, a treatment for osteogenesis imperfecta.

In terms of financial position, Mereo's total assets decreased to $40.6 million as of March 31, 2026, down from $45.9 million at the end of 2025. Cash and cash equivalents also fell to $36.2 million from $41.0 million. The company’s accumulated deficit increased to $507.5 million, reflecting ongoing investments in research and development without any revenue from product sales, as Mereo has yet to commercialize any of its product candidates.

Strategically, Mereo continues to focus on its late-stage clinical product candidates, including setrusumab and alvelestat, both of which have received orphan drug designations from regulatory authorities. The company is also advancing its early-stage program, vantictumab, with development funded by its partner, āshibio, Inc. Mereo's strategy involves acquiring and developing product candidates that have already received significant investment and possess substantial clinical data, which it believes will facilitate regulatory approval and market entry.

Operationally, Mereo has made progress in its clinical trials, with the completion of large Phase 2 studies for setrusumab and ongoing preparations for potential Phase 3 studies. The company reported a foreign currency transaction gain of $1.6 million in the first quarter of 2026, a notable turnaround from a loss of $2.8 million in the prior year. Mereo's employee headcount remains stable, supporting its ongoing research and development efforts.

Looking ahead, Mereo anticipates that its current cash reserves will be sufficient to fund operations into mid-2027. However, the company acknowledges the need for additional funding to support its development plans and potential commercialization of its product candidates. Mereo's management continues to explore various financing options, including public or private equity and non-dilutive funding sources, to ensure the continuation of its operations and development programs.